Tocilizumab treatment for new‐onset refractory status epilepticus

Abstract

We investigated the therapeutic potential of the interleukin‐6 receptor inhibitor tocilizumab in 7 patients with new‐onset refractory status epilepticus (NORSE) who remained refractory to conventional immunotherapy with rituximab (n=5) or without rituximab (n=2). Status epilepticus (SE) was terminated after 1‐2 doses of tocilizumab in six patients with a median interval of three days from the initiation. They had no recurrence of SE during the observation. However, two patients experienced severe adverse events related to infection during the tocilizumab therapy. Further prospective controlled studies are warranted to validate the efficacy and safety of tocilizumab in patients with NORSE.

This article is protected by copyright. All rights reserved.

https://ift.tt/2PV4H0g